-
1 Comment
Xiamen Amoytop Biotech Co., Ltd is currently in a long term uptrend where the price is trading 0.7% above its 200 day moving average.
From a valuation standpoint, the stock is 76.5% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 17.0.
Based on the above factors, Xiamen Amoytop Biotech Co., Ltd gets an overall score of 1/5.
| CurrencyCode | CNY |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | SHG |
| ISIN | CNE100003RT3 |
| Dividend Yield | 0.0% |
|---|---|
| PE Ratio | 31.34 |
| Target Price | 72.51 |
| Beta | -0.17 |
| Market Cap | 30B |
Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China and internationally. It offers various drug products, such as pegsomatropin injection, pegfilgrastim injection, molgramostim, filgrastim, and oprelvekin; active pharmaceutical ingredients (APIs); and reagents to treat viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is headquartered in Xiamen, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 688278.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
